Saveo is a B2B healthtech startup based in Bengaluru, India, that runs a marketplace supplying medicines to pharmacies.

This Startup Deep Dive explains what Saveo does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Saveo in Brief

• What it is: Saveo is an Indian B2B pharma marketplace company based in Bengaluru.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Operates a B2B pharmacy marketplace where pharmacies buy from one platform instead of many suppliers.
• Sells generics, surgical supplies, OTC products, specialty medicines and allopathic and ayurvedic medicines.
• Claimed 40,000+ live SKUs in 2021.
• Funding: About US$20 million per one report (Entrackr); an aggregator lists roughly Rs 593.8 million (about US$7 million); reports differ.

Saveo Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Saveo?

Saveo operates in the B2B pharma marketplace space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Saveo.

• Operates a B2B pharmacy marketplace where pharmacies buy from one platform instead of many suppliers.
• Sells generics, surgical supplies, OTC products, specialty medicines and allopathic and ayurvedic medicines.
• Claimed 40,000+ live SKUs in 2021.
• Replaces field salespeople with a full-stack tech platform.

The Origin Story of Saveo

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Amit Kumar, Anurag Savarnya, Shivansh Shrivastava, Vivek Jaiswal.
• Founded in August 2019 in Bengaluru by four IIT alumni: Amit Kumar, Anurag Savarnya, Shivansh Shrivastava and Vivek Jaiswal.
• Built a B2B pharmacy marketplace to replace field sales with technology in a fragmented medicine supply chain.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the B2B pharma marketplace sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• August 2019: founded.
• March 2020: Rs 2 crore raised from India Quotient and First Cheque, with Better Capital and angels.
• January 2021: US$4 million seed (about Rs 29.1 crore) co-led by Matrix Partners India and RTP Global, with Incubate Fund and India Quotient; angels included Kunal Shah and Rajesh Yabaji.
• January 2021: grew from 70+ pharmacies in Bengaluru in January 2020 to 3,000+ across Karnataka.
• About 2022: second seed round of US$4.5 million reported by Inc42.
• FY24: revenue of Rs 196 crore with loss narrowed to Rs 38.5 crore.

Saveo Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• March 2020: Rs 2 crore from India Quotient and First Cheque, with Better Capital and angels.
• January 2021: US$4 million seed co-led by Matrix Partners India and RTP Global, with Incubate Fund and India Quotient.
• About 2022: US$4.5 million second seed round (reported).
• Cap table (FY24 filings): Matrix Partners about 11.81%, RTP Global about 10.42%, India Quotient about 9.06%.

How Does Saveo Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Trading margin on medicines sold to pharmacies; medicine sales were its sole revenue source in FY24.
• A 2022 report said the margin was about 10.5% after discounts (reported).
• Procurement cost is 78% of total expenses, so profit depends on volume and sourcing terms.

The Numbers: Saveo Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY24 revenue from operations: Rs 196 crore, up 16.7% from Rs 168 crore in FY23.
• FY24 loss: Rs 38.5 crore, down 16% from Rs 46 crore in FY23.
• FY24 total expenses: about Rs 235 crore, including Rs 184 crore on medicine procurement; employee costs fell 24% to Rs 28 crore.
• Spent Rs 1.20 to earn each rupee of revenue in FY24, versus Rs 1.27 in FY23.

Market Opportunity for Saveo

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Targets India's fragmented medical supply chain, selling to pharmacies; the company pitches a single distribution point for the roughly 650,000 retailers in India (company-stated).

Technology and Product at Saveo

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Full-stack tech platform for ordering, pricing and logistics that substitutes for field sales teams.

Team and Culture at Saveo

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Four IIT-alumni co-founders run the company; Vivek Jaiswal is among those quoted as co-founder.

Saveo Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Saveo

• Thin margins: procurement is 78% of expenses and the business still lost Rs 38.5 crore in FY24.
• Funding totals are inconsistent across sources and no round after about 2022 was confirmed.
• Distribution depends on pharma manufacturers' and retailers' trading terms.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Saveo Growth Outlook: What to Watch

• Narrowing losses and improving cost per rupee of revenue suggest a path toward better unit economics.
• Funds were meant to deepen existing geographies, enter new territories and scale the tech platform.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Saveo can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Saveo Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Saveo

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Saveo.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Saveo

Studying a company in the B2B pharma marketplace space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Saveo.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Saveo as a Startup

• Customer clarity: Can Saveo name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Saveo is part of India’s growing B2B pharma marketplace ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Saveo FAQs: Frequently Asked Questions

What is Saveo?

Saveo is a B2B healthtech startup based in Bengaluru, India, that runs a marketplace supplying medicines to pharmacies. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Saveo?

Saveo was founded by Amit Kumar, Anurag Savarnya, Shivansh Shrivastava, Vivek Jaiswal, and the company reports a founding year of 2019 (August).

How much funding has Saveo raised?

About US$20 million per one report (Entrackr); an aggregator lists roughly Rs 593.8 million (about US$7 million); reports differ. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Saveo make money?

Saveo earns revenue from its B2B pharma marketplace products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Saveo?

Reported rivals include Medikabazaar, Retailio. See the competitor comparison above for how they differ.

What are the main risks for Saveo?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Faircent — Faircent: the Gurugram P2P lending platform | Paysharp — Paysharp: Chennai fintech with flat-fee B2B payments and RBI PA licence. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.